Most people share their end of year roundup during late December when everyone is too full of cake to read. Now you’re back in the saddle, here’s our roundup of everything the DataLab threw out into the world over the previous 12 months!
OpenPrescribing.net went from strength to strength, with over 135,000 unique users last year. We now have over 80 measures of prescribing safety, efficacy and cost-effectiveness and have been working on new types of measures and alerts to identify “outlier” prescribing, such as with zuclopenthixol. In 2019 we also: launched new dashboards and bespoke alerts for every single primary care network (PCN), sustainability and transformation partnership (STP), and NHS region; upgraded the Analyse page to support more organisations with bespoke medicines queries; and developed tools to help solve the problem of Ghost Branded Generics which cost the NHS an extra £11.6million per annum but has massively reduced during 2019.
In 2019 we were delighted to obtain some funding for OpenPathology.net which aims to do for blood tests what OpenPrescribing did for medicines. We have toiled hard this year, setting up the infrastructure and data processing, negotiating and obtaining access to data, and creating an exciting detailed dashboard. While we continue to finalise our pilot for a full launch, on OpenPathology.net you can find blogs describing our insights and sign up to our newsletter for updates.
2019 saw a number of key milestones for our research integrity work. The EU and FDAAA TrialsTracker continue to publicly document which trials are reporting under European and US guidelines; we highlighted unreported trials in the BMJ; saw the publication of the COMPare project (here & here); and advocated for researchers to share their analytic code. Our work has had a major policy impact in the UK as the Commons Science and Technology Select Committee used our data in letters to UK universities and NHS Trusts about their trial reporting, and then followed up to ensure accountability. Our research paper on failure to comply with the FDA requirements to report trials onto clinicaltrials.gov was published in The Lancet. This was a good year in the battle to improve clinical trial reporting: make sure you sign up to the AllTrials.net campaign so we can all maintain the pressure!
As well as building useful tools for coalface clinicians we continue to publish traditional academic papers in high impact journals. All our traditional research can be read on our website and highlights from this year include:
Variation in responsiveness to warranted behaviour change among NHS clinicians: novel implementation of change detection methods in longitudinal prescribing data This study was published in the BMJ in October alongside an editorial and a podcast featuring Ben. We used a model developed by our collaborator Felix Pretis to detect how practices change their prescribing. We are very excited about this method and are currently developing new tools that can improve clinical practice by better identifying, understanding, and reducing unwarranted variation in care using this method.
Measuring the Impact of an Open Web-Based Prescribing Data Analysis Service on Clinical Practice: Cohort Study on NHS England Data Our price per unit tool remains very popular (see Youtube explainer) and in January we published our evaluation in JMIR where we estimated a total saving since launch of £243 thousand at practice level and £1.47 million at CCG level between the feature launch and end of our four month follow-up (August to November 2017) among practices viewed. You can find your own price per unit tool on your organisation’s dashboard.
Impact of Chief Medical Officer Activity on Prescribing of Antibiotics in England – An Interrupted Time Series Analysis In 2019, Professor Dame Sally Davies stepped down as Chief Medical Officer and is now is the UK Special Envoy on Antimicrobial Resistance. We cannot firmly attribute causality but her actions and antimicrobial strategy over recent years appears to have had a substantial impact on prescribing antibiotics at the population level in England.
Do doctors in dispensing practices with a financial conflict of interest prescribe more expensive drugs? A cross-sectional analysis of English primary care prescribing data Early in 2019 we found that doctors in dispensing practices are more likely to prescribe higher cost drugs. This has important implications more broadly than for dispensing practices, as it demonstrates that clinical decision-making may not be solely driven by patient need, and that unwarranted variation in care may be partly driven by financial factors for the doctor.
Why researchers should share their analytic code At the DataLab we share all our code openly on our GitHub account for inspection and reuse. We think transparency is important for all researchers using code to generate insight and in November we wrote an editorial for the BMJ following the retraction of a trial due to a serious programming error. We will be sharing more of our thoughts on open data and analysis in our new policy unit throughout 2020.
We have loads more papers coming soon and we have chosen to preprint many of them on our research page. Sign up to our monthly newsletter and to get updates on our papers throughout the year.
In 2019 we continued our popular blogging as it is a really good way of sharing analyses and short projects with the wider community for input, reuse and open discussion. We know there are lots of people out there working on NHS data for practical coalface uses, and we would really love to read more people blogs. Please send us your blogs or get in touch if you would like to write a guest blog on our site like this one on high-dose dexamethasone. Our top 10 most read blogs of 2019 were:
- Prescribing Data: What is a BNF code?
- OpenPathology is go! We are hiring!
- Ghost branded generics: Why does the cost of generic atorvastatin vary?
- Ghost Branded Generics: A new dashboard on OpenPrescribing
- Price Concessions Calculator – A New Feature on OpenPrescribing
- Communicating variation in prescribing – Why We Use Deciles
- Ghost Branded Generics – How to fix it
- Ghost Branded Generics – Positive News!
- NHS price concessions cost charities and local authorities an additional £5.6 million last year
- Why is openness and transparency important for good data analysis and how does OpenPrescribing embody it?
New team members
We welcomed new people to our team. Hilary Winstanly joined us in the spring and has been busy helping Ben and the team with various administrative duties. Jess Morley and Henry Drysdale started in the autumn and have been busy making preparations for our DataLab Policy Insights work coming next year. Caroline Morton is a GP, epidemiologist and coder who is developing our teaching programme. Finally, a big shout out to Ieva, Michael and Orla who have also recently joined the team and are working on some exciting projects you’ll hear more about in 2020.
The future contains excitement. We will be promoting open analytic methods to the world, with teaching and advocacy, and we will shortly be launching a policy thinktank on better use of data and evidence. We will be championing best practice, and shining a light on important flaws. We have new projects to launch, a ton of new features, and a slew of new papers.
Our cause is just, and shall prevail!